Contrasting Clarus Therapeutics (CRXT) & Its Rivals

Clarus Therapeutics (NASDAQ:CRXTGet Rating) is one of 270 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Clarus Therapeutics to related companies based on the strength of its valuation, risk, analyst recommendations, earnings, institutional ownership, profitability and dividends.

Risk & Volatility

Clarus Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Clarus Therapeutics’ peers have a beta of 0.69, meaning that their average stock price is 31% less volatile than the S&P 500.

Valuation and Earnings

This table compares Clarus Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Clarus Therapeutics $13.96 million -$40.62 million -0.02
Clarus Therapeutics Competitors $754.48 million $143.11 million 4.82

Clarus Therapeutics’ peers have higher revenue and earnings than Clarus Therapeutics. Clarus Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

9.3% of Clarus Therapeutics shares are held by institutional investors. Comparatively, 47.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 5.3% of Clarus Therapeutics shares are held by insiders. Comparatively, 16.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Clarus Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clarus Therapeutics -193.00% N/A -87.75%
Clarus Therapeutics Competitors -4,225.43% -197.41% -33.82%

Analyst Ratings

This is a breakdown of current ratings for Clarus Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clarus Therapeutics 0 2 2 0 2.50
Clarus Therapeutics Competitors 686 3574 10321 152 2.67

Clarus Therapeutics presently has a consensus price target of $7.90, indicating a potential upside of 27,094.49%. As a group, “Biological products, except diagnostic” companies have a potential upside of 91.80%. Given Clarus Therapeutics’ higher probable upside, equities research analysts plainly believe Clarus Therapeutics is more favorable than its peers.

Summary

Clarus Therapeutics peers beat Clarus Therapeutics on 9 of the 13 factors compared.

Clarus Therapeutics Company Profile

(Get Rating)

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.